Asaf Toker

Title : Personalized tissues and organs replacement A peek into the future

Abstract:

Matricelf developed  a  technology  that  enables  the  production of  autologous  engineered  tissue  composed of  matrix and cells derived from patients Omentum biopsy. The platform showed remarkable pre-clinical results for several medical conditions. The company recently licensed the technology that enabled scientist at Tel Aviv university that 3D printed a human  heart  from  human  cells  and  matrix  for  the  first  time  in  human  history.  The  company  plans  to  conduct  its  first  human clinical trial for Acute Spinal Cord Injury (SCI) in 2022.

Biography:

Dr. Toker is a seasoned CEO with a proven track record in the biotechnology and healthcare industries. He possesses strong business development skills with prior experience in medical devices, R&D, and Life Sciences. Dr. Toker is a paediatrician and also has a degree in Health Systems Management and MSc in Biotechnology Engineering from Ben Gurion University of the Negev. Dr  Toker  served  in  several  executive  positions  in  the  private  and  public  healthcare  system  and  served  as  a  director  in  several  biotechnology and medical device companies.